FinTrust Capital Advisors’s Haemonetics HAE Stock Holding History

FinTrust Capital Advisors’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-595	Closed	-$50.9K	–	1288
2023 Q4	$50.9K	Buy	595 +5	+0.8%	+$432	0.01%	482
2023 Q3	$52.9K	Sell	590 -159	-21%	-$14.2K	0.01%	445
2023 Q2	$58.9K	Sell	749 -2,000	-73%	-$169K	0.01%	423
2023 Q1	$224K	Hold	2,749	–	–	0.05%	245
2022 Q4	$216K	Buy	2,749 +2,000	+267%	+$161K	0.05%	253
2022 Q3	$60K	Buy	+749	New	+$53.8K	0.02%	473
2021 Q2	–	Sell	-25	Closed	-$3K	–	1188
2021 Q1	$3K	Hold	25	–	–	﹤0.01%	1062
2020 Q4	$3K	Hold	25	–	–	﹤0.01%	992
2020 Q3	$2	Hold	25	–	–	﹤0.01%	1062
2020 Q2	$2K	Hold	25	–	–	﹤0.01%	926
2020 Q1	$2K	Hold	25	–	–	﹤0.01%	1000
2019 Q4	$3K	Hold	25	–	–	﹤0.01%	934
2019 Q3	$3K	Hold	25	–	–	﹤0.01%	943
2019 Q2	$3K	Hold	25	–	–	﹤0.01%	907
2019 Q1	$2K	Hold	25	–	–	﹤0.01%	1095
2018 Q4	$3K	Buy	+25	New	+$2.63K	﹤0.01%	1043

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FinTrust Capital Advisors's HAE Position: Q1 2024 in Review

FinTrust Capital Advisors sold out of Haemonetics (HAE) in Q1 2024, closing a stake of 595 shares — an estimated $50.9K sold.

FinTrust Capital Advisors first reported a position in HAE in Q4 2018 and held it in 16 quarters. The position peaked at $224K in Q1 2023. 298 funds tracked by Wall St. Rank hold HAE as of Q1 2024.

FinTrust Capital Advisors reported no remaining Haemonetics position as of Q1 2024 after selling out during the quarter.
FinTrust Capital Advisors sold 595 Haemonetics shares in Q1 2024, an estimated $50.9K.
FinTrust Capital Advisors first reported a position in Haemonetics in Q4 2018 and held it in 16 quarters.
FinTrust Capital Advisors's Haemonetics position peaked at $224K in Q1 2023.
298 funds tracked by Wall St. Rank held Haemonetics as of Q1 2024.

Based on FinTrust Capital Advisors's 13F filing for Q1 2024, filed 2 May 2024.